Leukemia Therapeutics Market : Increasing Prevalence of Leukemia among Geriatric Population to Boost Market Growth -Transparency Market Research

Leukemia refers to the type of blood cancer that leads to the abnormal production of blood cells, especially leukocytes (white blood cells). Abnormal leukocytes lose their ability to fight against infections. Some types of leukemia appear suddenly and progress fast over days to weeks, whereas other types progress slowly over months to years. It has been observed that genetic factors, unhealthy lifestyle, high exposure to radiations, and various other environmental factors trigger leukemia. According to the World Cancer Research Fund International, in 2012, 352,000 new cases of leukemia were diagnosed globally.  Rising number of patients affected by leukemia will propel the growth of the global leukemia therapeutics market.

Rising Geriatric Population to Boost Global Leukemia Therapeutics Market

It has been observed that leukemia cases are more common in adults and progress with age. High prevalence of leukemia among rapidly growing geriatric population worldwide will increase the demand for leukemia therapeutics. Further, increased investment in innovation, and research and development by pharmaceutical and biotechnology firms in the field of oncology will push the growth of the global leukemia therapeutics market. Promising pipeline products and introduction of novel therapies will also augment the market growth in the near future. However, high cost of therapeutic drugs and treatments, coupled with a number of entry-to-market barriers, may restrict the overall leukemia therapeutics market.

Request For Brochure: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=6487

Chemotherapy and Radiation Therapy are Most Common Treatment Methods in Global Leukemia Therapeutics Market

Depending on the disease condition, the global leukemia therapeutics market has been segmented into chronic lymphocytic leukemia, chronic myeloid leukemia, acute lymphocytic leukemia, and acute myeloid leukemia. In 2014, chronic myeloid leukemia dominated the global leukemia therapeutics market. Patients suffering from chronic myeloid leukemia show increased susceptibility to bacterial infections, anemia, thrombocytopenia, and enlarged spleen. The treatment for chronic myeloid leukemia includes stem cell transplants, biologic therapies, and chemotherapy.

On the basis of treatment, the global leukemia therapeutics market has been categorized into radiation therapy, immunotherapy, chemotherapy, bone marrow transplant, targeted therapy, surgery, and stem cell therapy. Chemotherapy and radiation therapy are the two most common treatment methods of leukemia. Targeted therapies are newer treatment methods that can be administered to patients suffering from leukemia along with chemotherapy. In global leukemia therapeutics market, stem cell therapy and bone marrow transplant are the emerging trends and are expected to boost the market in the coming years. 

According to the drugs used for treating leukemia, the global leukemia therapeutics market has been segmented into drug classes such as kinase inhibiting drugs, immunomodulatory dugs, aminopeptidase inhibitors, and others. GA101, fludarabine, cyclophosphamide, and sapacitabine are some of the most promising drugs in the clinical trials. 

Growing Demand for Leukemia Therapeutics in Asia Pacific and South America

Geographically, the global leukemia therapeutics market has been dominated by North America, followed by Europe. The World Health Organization estimates that the prevalence of leukemia in developed regions such as North America and Europe would be high due to genetic factors. In emerging countries of Asia Pacific such as India and China, and in South America countries such as Mexico and Brazil, the demand for leukemia therapeutics is expected to soar owing to growing awareness level among patients and rapidly developing medical infrastructure.

Some of the key players in the global leukemia therapeutics market are Celgene Corporation, F. Hoffmann-La Roche AG, Novartis AG, GlaxoSmithKline, Bristol Myers Squibb Company (BMS), Pfizer Inc., Biogen, and Eisai Co. Ltd

Browse Full Global Leukemia Therapeutics Market Report With Complete TOC @ http://www.transparencymarketresearch.com/leukemia-therapeutics-market.html

About Us

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

TMR’s data repository is continuously updated and revised by a team of research experts so that it always reflects the latest trends and information. With extensive research and analysis capabilities, Transparency Market Research employs rigorous primary and secondary research techniques to develop distinctive data sets and research material for business reports.

Contact

Mr. Nachiket Ghumare
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com